<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837277</url>
  </required_header>
  <id_info>
    <org_study_id>SevereHIV</org_study_id>
    <nct_id>NCT01837277</nct_id>
  </id_info>
  <brief_title>Impact of a Raltegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação Bahiana de Infectologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundação Bahiana de Infectologia</source>
  <brief_summary>
    <textblock>
      The current available antiretroviral (ARV) agents make possible a successful treatment of
      virtually all HIV-infected patients, but some problems related to early mortality are still
      of concern, mainly in resources-limited settings. There are several published reports showing
      that such patients are at a significantly higher risk of death during the first months of
      treatment, in comparison with the observed outcomes in developed countries. One of the
      consistently detected risks for early mortality across these reports is the baseline low CD4
      count, although it does not seem to be the only reason for such outcome. In Brazil and other
      developing countries, there is still a large proportion of AIDS patients who are diagnosed
      with AIDS, or only seek health care for HIV infection late in the course of disease.
      Raltegravir (RAL), the first HIV-1 integrase inhibitor, is a potent and safe ARV drug. The
      available evidence suggest it promotes a faster decline in HIV-1 plasma viremia, and a higher
      increase in CD4 cells count, in comparison with those in Efavirenz (EFV) arm. The
      investigators propose to compare the impact of RAL versus EFV in the early mortality rates
      for severely ill (CD4+ cells count &lt;50 cells/mm3) patients starting ARV therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>early mortality</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 count</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Severely Immunocompromised HIV Patients</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Patients will receive ART regimen based on investigational drug Raltegravir 400 mg BID + TDF 300 mg QD+ 3TC 150 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Patients will receive ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Use of Raltegravir-based regimens</intervention_name>
    <description>Use of Raltegravir-based regimens: patients will receive a Raltegravir-based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz-based regimens</intervention_name>
    <description>Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)</description>
    <arm_group_label>Efavirenz</arm_group_label>
    <other_name>Efavirenz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA
             &gt;1,000 copies/ml)

          -  No previous use of any ARV drug (drug-naïve patients)

          -  Presence of clinical symptoms according to Rio de Janeiro / Caracas´ AIDS definition
             (Asthenia, Cachexia/Wasting, Cough, Dermatitis, persistent, Diarrhea, Fever,
             Lymphadenopathy, Candidiasis, oral, or hairy leukoplasia, Central nervous system
             dysfunction, Herpes zoster in individual younger than 60 years of age)), and/or any
             active AIDS-defining condition

          -  Baseline CD4+ cells count equal or lower than 50 cells/mm3

          -  Age equal or higher than 18 years

          -  HIV-1 plasma viral load ≥ 1,000 copies of HIV-1 RNA/ml

        Exclusion Criteria:

          -  Undetectable plasma viral load at screening

          -  CD4 cells count&gt;50 cells/mm3

          -  Asymptomatic individuals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Estela Luz, RN, MSci</last_name>
    <phone>557132838123</phone>
    <email>eluz5@yahoo.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundação Bahiana de Infectologia/SEI</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40010-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Estela Luz, RN, MSci</last_name>
      <phone>32838123</phone>
      <email>eluz5@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Carlos Brites, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabianna Bahia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Ponze, RN</last_name>
      <phone>5521222739073</phone>
    </contact>
    <investigator>
      <last_name>Mauro Schechter, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priscila Pelaez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Sprinz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundação Bahiana de Infectologia</investigator_affiliation>
    <investigator_full_name>Carlos Brites</investigator_full_name>
    <investigator_title>Senior Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

